Astera Labs (NASDAQ:ALAB) Stock Gets Price Target Reduction from Royal Bank Of Canada

Astera Labs (NASDAQ:ALAB) had its target price decreased by Royal Bank Of Canada from $500.00 to $400.00 in a research note released on Wednesday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Other research analysts have also recently issued reports about the stock. Northland Securities upgraded shares of Astera Labs from a “market perform” rating to an “outperform” rating and set a $315.00 price target on the stock in a report on Wednesday. Zacks Research lowered shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Morgan Stanley boosted their price objective on shares of Astera Labs from $240.00 to $335.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Citigroup downgraded shares of Astera Labs from a “buy” rating to a “hold” rating in a research note on Friday, October 9th. Finally, Weiss Ratings lowered shares of Astera Labs from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, October 23rd. Thirteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Astera Labs has a consensus rating of “Moderate Buy” and a consensus price target of $320.85.

Astera Labs Stock Up 6.3%

ALAB traded up $11.24 during trading hours on Wednesday, reaching $190.71. 6,642,738 shares of the company’s stock traded hands, compared to its average volume of 4,244,483. The firm has a 50-day moving average price of $300.46 and a 200 day moving average price of $255.80. The firm has a market capitalization of $33.09 billion, a PE ratio of 75.98 and a beta of 3.85. Astera Labs has a 52-week low of $97.89 and a 52-week high of $499.48.

Astera Labs (NASDAQ:ALAB) last released its earnings results on Tuesday, November 3rd. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.13. Astera Labs had a return on equity of 19.24% and a net margin of 30.74%. The business had revenue of $584.90 million for the quarter, compared to analyst estimates of $550.78 million. During the same quarter last year, the firm posted $0.49 earnings per share. The business’s revenue was up 153.6% compared to the same quarter last year. Equities analysts predict that Astera Labs will post 2.71 EPS for the current fiscal year.

Insider Buying and Selling at Astera Labs

In other news, General Counsel Philip Mazzara sold 6,801 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $340.50, for a total transaction of $2,315,740.50. Following the transaction, the general counsel owned 96,542 shares in the company, valued at approximately $32,872,551. This trade represents a 6.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Manuel Alba sold 183,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $280.13, for a total value of $51,263,790.00. Following the transaction, the director owned 253,863 shares in the company, valued at approximately $71,114,642.19. This represents a 41.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 396,059 shares of company stock worth $123,408,470. Insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Greenleaf Trust increased its position in Astera Labs by 1.8% during the 2nd quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock valued at $966,000 after purchasing an additional 36 shares during the period. Parkside Financial Bank & Trust lifted its position in shares of Astera Labs by 74.5% in the 2nd quarter. Parkside Financial Bank & Trust now owns 96 shares of the company’s stock worth $46,000 after purchasing an additional 41 shares during the period. Integrated Advisors Network LLC lifted its position in shares of Astera Labs by 4.8% in the 3rd quarter. Integrated Advisors Network LLC now owns 983 shares of the company’s stock worth $350,000 after purchasing an additional 45 shares during the period. Interchange Capital Partners LLC lifted its position in shares of Astera Labs by 4.4% in the 3rd quarter. Interchange Capital Partners LLC now owns 1,187 shares of the company’s stock worth $423,000 after purchasing an additional 50 shares during the period. Finally, Glenmede Trust Co. NA boosted its stake in shares of Astera Labs by 2.7% during the first quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock valued at $209,000 after purchasing an additional 51 shares in the last quarter. 60.47% of the stock is currently owned by institutional investors.

Key Headlines Impacting Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Astera Labs reported Q3 revenue of $584.9 million, up 154% year over year, and its Scorpio switch business was highlighted as a major growth driver. One Seeking Alpha contributor upgraded the stock, citing Scorpio’s momentum and gross margins that may stabilize near 72%. Astera Labs: So Much To Like In Q3 (Upgrade)
• Positive Sentiment: BMO Capital initiated coverage with an Outperform rating and a $375 price target; Northland Securities also upgraded the stock to Outperform. These calls provide a counterpoint to recent selling and valuation worries. BMO Capital Initiates Coverage on Astera Labs With Outperform Rating Astera Labs Upgraded to Outperform at Northland Securities
• Neutral Sentiment: Analyst views remain divided, with one recent opinion arguing that the selloff may already reflect a potential growth slowdown in 2027. Astera Labs: Sell-Off Already Priced In 2027 Stall
• Negative Sentiment: A reported analyst downgrade triggered renewed pressure, while coverage also points to ALAB’s rich valuation after its Q3 results. Those concerns may amplify selling when technology stocks are broadly weak. Shares Gap Down After Analyst Downgrade Stock Drops After Q3 Results Spotlight Rich Valuation
• Negative Sentiment: Astera Labs was caught in a wider technology-sector selloff, adding market-wide pressure beyond company-specific news. Astera Labs Falls Amid Tech Selloff

Astera Labs Company Profile

Astera Labs, Inc is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help move data among processors, accelerators, memory and other components in high-performance computing systems.

The company’s portfolio includes Aries PCIe and CXL retimers, Taurus Ethernet smart cable modules, Scorpio fabric switches and Leo CXL memory connectivity controllers. Astera Labs also offers software tools to help customers configure and monitor its connectivity products.

Founded in 2017 and headquartered in Santa Clara, California, Astera Labs serves the global cloud and computing markets.